The Future of Genetic Therapeutics

Discovering life-changing scientific and medical advancements

Nature Medicine Paper
MISSION

We are revolutionizing treatment approaches for myelin-based disorders.

Myrtelle is transforming the treatment of myelin-based diseases, including white matter disorders (Leukodystrophies).

Our platform enables us to address an array of diseases with white matter involvement.

OUR VISION

We are dedicated to changing the treatment, abilities, and quality of life of those afflicted by devastating neurological disorders for whom few, if any, treatment options exist.

Learn More
CLINICAL TRIAL

Learn more about our innovative clinical work for the treatment of the rare disorder, Canavan disease

More Info
TECHNOLOGY

Our proprietary technologies enables innovative approaches to hundreds of disorders involving myelin.

Explore Technology

Understanding Gene-Therapy In Canavan Disease

STRATEGIC PARTNERSHIPS

Collaborations that Lead to Change

Our strategic partnerships enable us to advance our mission through alliances in scientific research, development, manufacturing, and more, including an exclusive IP license with Pfizer Inc.

  • Viral Gen
  • Charles River
LEARN MORE

Understanding Gene Therapy for Rare CNS Diseases

Download